Key statistics dashboard for ImageneBio Inc (IMA). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc.
Stock Data
| Price | $4.93 |
| Market Cap | $56M |
| Beta | 0.55 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.94 |
| Price / Book | 0.56 |
| P/S | 0.00 |
| P/FCF | -0.96 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 21.47 |
| Quick Ratio | 21.47 |
| Cash Ratio | 14.40 |
| Debt / Equity | 0.01 |
| Debt / Assets | 1.26% |
| Interest Coverage | -614.18 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 8.79 |
| Cash per share | 8.42 |
| FCF per share | -3.57 |
| Tangible Book Value per share | 8.79 |
| Dividend per share | 0.00 |
Related companies: ARTV · CNTB · CNTX · IFRX · KLRS · MGX · OVID
Explore sector: Healthcare · Biotechnology
More sections of IMA: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks